PMID- 7831680
OWN - NLM
STAT- MEDLINE
DCOM- 19950217
LR  - 20190727
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 75
IP  - 6
DP  - 1994 Sep 15
TI  - Inhibitory effects of TFPI on thrombin and factor Xa generation in 
      vitro--modulatory action of glycosaminoglycans.
PG  - 609-16
AB  - The effect of tissue factor pathway inhibitor (TFPI) on thrombin and factor Xa 
      generation was studied in an in vitro system using a prothrombin complex 
      concentrate. It was found that TFPI, via the direct inhibition of factor Xa and 
      the tissue factor/factor VIIa complex, inhibited both the further generation of 
      factor Xa and the generation of thrombin in a concentration-dependent manner. The 
      generation of thrombin (IC50 255 ng/ml) was more pronounced than that of factor 
      Xa (IC50 684 ng/ml). The inhibitory activity of TFPI was significantly enhanced 
      when unfractionated heparin was present in the assay system at a concentration of 
      10 micrograms/ml which did not show any inhibitory effects on protease generation 
      in the same system. Furthermore, the influence of TFPI at subthreshold 
      concentrations (100 ng/ml and 200 ng/ml, resp.) on the inhibitory action of 
      unfractionated heparin (UFH), a low molecular weight heparin (LMWH), heparan 
      sulfate (HS) and the synthetic heparin pentasaccharide (PS) was investigated. 
      Whereas in the concentration range used (0.3-40 micrograms/ml) these 
      glycosaminoglycans did not inhibit thrombin and factor Xa generation, after 
      supplementation of the system with TFPI a concentration-dependent inhibition of 
      the generation of the proteases up to 40-50% was seen for UFH, LMWH and HS. TFPI 
      did not increase the activity of PS.
FAU - Kaiser, B
AU  - Kaiser B
AD  - Loyola University Medical Center, Department of Pathology, Maywood, IL.
FAU - Hoppensteadt, D A
AU  - Hoppensteadt DA
FAU - Jeske, W
AU  - Jeske W
FAU - Wun, T C
AU  - Wun TC
FAU - Fareed, J
AU  - Fareed J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (Lipoproteins)
RN  - 0 (Oligosaccharides)
RN  - 0 (lipoprotein-associated coagulation inhibitor)
RN  - 88096-19-9 (IC 831423)
RN  - 9005-49-6 (Heparin)
RN  - 9035-58-9 (Thromboplastin)
RN  - 9050-30-0 (Heparitin Sulfate)
RN  - EC 3.4.21.21 (Factor VIIa)
RN  - EC 3.4.21.5 (Thrombin)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Animals
MH  - Factor VIIa/antagonists & inhibitors
MH  - Factor Xa/biosynthesis
MH  - *Factor Xa Inhibitors
MH  - Heparin/*pharmacology
MH  - Heparin, Low-Molecular-Weight/*pharmacology
MH  - Heparitin Sulfate/*pharmacology
MH  - Lipoproteins/*pharmacology
MH  - Oligosaccharides/*pharmacology
MH  - Swine
MH  - Thrombin/*antagonists & inhibitors/biosynthesis
MH  - Thromboplastin/antagonists & inhibitors
EDAT- 1994/09/15 00:00
MHDA- 1994/09/15 00:01
CRDT- 1994/09/15 00:00
PHST- 1994/09/15 00:00 [pubmed]
PHST- 1994/09/15 00:01 [medline]
PHST- 1994/09/15 00:00 [entrez]
AID - 0049-3848(94)90173-2 [pii]
AID - 10.1016/0049-3848(94)90173-2 [doi]
PST - ppublish
SO  - Thromb Res. 1994 Sep 15;75(6):609-16. doi: 10.1016/0049-3848(94)90173-2.